Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)

About this update from Ascletis Pharma, Inc.

HONG KONG , May 5, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on the Phase I data of ASC47, an adipose-targeting thyroid hormone receptor beta (THRβ) agonist for muscle-preserving weight loss, which, in combination with semaglutide, demonstrated up to 111.8% greater relative weight loss in participants with obesity compared to semaglutide monotherapy, and a poster on the preclinical data of ASC36, a once-monthly next-generation amylin receptor agonist peptide, which demonstrated 32-day average observed half-life, 6-fold longer than petrelintide, in non-human primate (NHP) model and 91% more relative weight loss than petrelintide in diet-induced obese (DIO) rat model. Presentation details Title: ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy Session: Track 4: Obesity Management and Intervention (PO4.264 ) Date/Time: Thursday, 14 May, 2026, 18:00–19:15 TRT Title: ASC36, a Once-Monthly Next-Generation Amylin Receptor Agonist Peptide, Demonstrated 32-day Average Observed Half-life, 6-fold Longer than Petrelintide, in NHP Model and 91% More Relative Weight Loss than Petrelintide in DIO Rat Model Session: Track 4: Obesity Management and Intervention (PO4.270 ) Date/Time: Thursday, 14 May, 2026, 18:00–19:15 TRT Title: ASC35, a Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist Peptide, Demonstrated 14-day Average Observed Half-life, 6-fold Longer than Tirzepatide, in NHP Model and 71% More Relative Weight Loss than Tirzepatide in DIO Mouse Model Session: Track 4: Obesity Management and Intervention (PO4.263 ) Date/Time: Thursday, 14 May, 2026, 18:00–19:15 TRT Additional information about the ECO 2026 is available at https://eco2026.org/ . About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, an eloralintide-like potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 (GLP-1RA) and ASC39 (amylin RA), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK). For more information, please visit www.ascletis.com. Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) [email protected] Ascletis Pharma Inc. PR and IR Teams +86-181-0650-9129 (China) [email protected] [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/ascletis-to-present-data-on-multiple-programs-at-the-33rd-european-congress-on-obesity-eco-2026-302762737.html

View stock analysis, news, and events for Ascletis Pharma, Inc.